<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Viropharma Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/viropharma-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(THRX) Theravance Earns FDA Approval for Skin Infection Drug</title>
		<link>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265</link>
		<comments>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:22:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[Viropharma Incorporated]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15265</guid>
		<description><![CDATA[In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. Vibativ, jointly developed with Japan’s Astellas Pharma, is expected to hit the US market by end of this year. While the drug will be marketed and sold by Astellas, Theravance will receive royalties on global sales. In the U.S., the company will help Astellas in marketing the drug for the first three years post approval. Apart from cSSSI, Vibativ is also being studied for hospital-acquired pneumonia (HAP). The company has already submitted a New Drug Application (NDA) for this indication and has been assigned a Prescription Drug User Fee Act (PDUFA) date of Nov. 26. The approval ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Responds to FDA Questions on Antibiotic Drug Trials</title>
		<link>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144</link>
		<comments>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:39:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[Viropharma Incorporated]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14144</guid>
		<description><![CDATA[We are pleased to hear that the US Food and Drug Administration (FDA) has accepted Johnson &#38; Johnson’s (JNJ) response on clinical trial-related issues. Last month, the agency had warned the company for not maintaining proper records during the trial of ceftobiprole, a broad-spectrum antibiotic for the treatment of complicated skin infections and nosocomial pneumonia. J&#38;J had licensed the drug from Swiss drugmaker Basilea Pharmaceuticals in 2005. The issue must be resolved for the drug to be approved. The new drug application for ceftobiprole has been pending since May 2007. The approval is getting delayed since protocol-related issues have been present from the initial stages. In November last year, the FDA issued a Complete Response letter stating that it could not approve the new drug application at that time as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

